scispace - formally typeset
S

Shinae Kizaka-Kondoh

Researcher at Tokyo Institute of Technology

Publications -  110
Citations -  4936

Shinae Kizaka-Kondoh is an academic researcher from Tokyo Institute of Technology. The author has contributed to research in topics: Tumor hypoxia & Gene. The author has an hindex of 36, co-authored 102 publications receiving 4399 citations. Previous affiliations of Shinae Kizaka-Kondoh include Kyoto University.

Papers
More filters
Journal ArticleDOI

Identification of a Novel Thioredoxin-related Transmembrane Protein

TL;DR: The molecular cloning and characterization of one of transforming growth factor-β-responsive genes, designated TMX, that encodes a novel protein of 280 amino acid residues is reported, suggesting that the Trx-like activity of TMX may help relieve ER stress caused by brefeldin A.
Journal ArticleDOI

High resolution imaging of intracellular oxygen concentration by phosphorescence lifetime

TL;DR: Assessing the detailed distribution and dynamics of OC inside cells achieved by the presented system will be useful to understanding a physiological and pathological oxygen metabolism.
Journal ArticleDOI

Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals.

TL;DR: This model system using the 5HRE-luciferase reporter construct provides qualitative information (hypoxic status) of solid tumors and enables one to conveniently evaluate the efficacy of cancer therapy on hypoxia in malignant solid tumors.
Journal ArticleDOI

Intracellular CO release from composite of ferritin and ruthenium carbonyl complexes.

TL;DR: The protein cages enable us to increase the half-life for CO release, providing a release rate that is 18-fold slower than the rate of a typical CORM, Ru(CO)3Cl(glycinate) (CORM-3).
Journal ArticleDOI

Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer

TL;DR: The results show that HIF-1–active cells constitute a large proportion of invading and metastatic cells and suggest that eradication of these cells may improve the outcome in advanced pancreatic cancer, a condition for which no effective therapy currently exists.